In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® ...

Pain represents the cardinal symptom of osteoarthritis, yet its intensity, quality, and impact vary dramatically among ...

InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...

By Kilo MIKEGhana stands at an important crossroads in its democratic evolution. After more than three decades of relative constitutional stability, it has become increasingly clear that the current ...

Alabama treasure hunters have a not-so-secret headquarters in Irondale, and it’s housed in a sprawling red and white building ...

FOR many micro, small and medium-sized enterprises (MSMEs), the biggest challenge today is no longer product quality or consumer demand. It is access.

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

Access to capital remains one of the most persistent constraints facing entrepreneurs, investors, and institutions. Despite ...

Nigeria entered a new phase in its education journey with the rollout of the revised national curriculum in 2025. The reform ...